NATCO launches additional strengths for generic version of Revlimid in USA
News

NATCO launches additional strengths for generic version of Revlimid in USA

Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

  • By IPP Bureau | March 10, 2023

NATCO Pharma Limited announces the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries. 

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Upcoming E-conference

Other Related stories

Startup

Digitization